Table 2 Healthcare use of RSV infections in young children in the 14 days after enrollment
|  | Total (n = 116) | 1–12 months (n = 52) | 13–24 months (n = 25) | 25–60 months (n = 39) | p* | Lazio (n = 52) | Apulia (n = 64) | p* |
|---|---|---|---|---|---|---|---|---|
Healthcare usage$ | 87 (75%) | 45 (87%) | 18 (72%) | 24 (62%) | 0.024 | 31 (60%) | 56 (88%) | 0.001 |
Number of consultation to pediatrician after swab (median, IQR) | 1 (0–2) | 2 (1–3) | 1(0–2) | 1 (0–2) | 0.094 | 1 (0–2) | 2 (–3) | < 0.001 |
Number ofphone call/email after swab | 1 (0–2) | 1 (1–3) | 1 (0–2) | 1 (0–2) | 0.861 | 1 (0–2) | (1–3) | 0.025 |
Consultation with another doctor (sub-specialist) after swab n (%) | 11 (9%) | 5 (10%) | 1 (4%) | 5 (13%) | 0.501 | 5 (10%) | 6 (9%) | 0.965 |
Emergency department n (%) | 18(16%) | 11 (21%) | 3 (12%) | 4 (10%) | 0.314 | 3 (6%) | 15 (23%) | 0.009 |
Hospitalizations n (%) | 7 (6%) | 6 (12%) | 0 (-) | 1 (3%) | 0.074 | 2 (4%) | 5 (8%) | 0.372 |
Days of hospitalizations (median, IQR) | 7 (3–9) | 7 (3–9) | - | 4 (4–4) | 0.611 | 2.5 (–3) | 7 (7–9) | 0.049 |
Use of medications and prophylaxes | Â | Â | Â | Â | Â | Â | Â | Â |
Paracetamol | 47 (43%) | 14 (30%) | 16 (64%) | 17 (44%) | 0.024 | 15 (31%) | 32 (52%) | 0.021 |
Other pain medication (e.g. ibuprofen) | 4 (4%) | 0 (-) | 0 (-) | 4 (10%) | 0.023 | 2 (4%) | 2 (3%) | 0.823 |
Antibiotics | 34 (31%) | 8 (17%) | 10 (40%) | 16 (41%) | 0.034 | 15Â (31%) | 19 (31%) | 0.952 |
Bronchodilators | 38 (31.9%) | 18 (34%) | 10 (38.6%) | 10 (25%) | 0.160 | 38 (69.1%) | 0 | < 0.001 |
Steroids | 6 (5%) | 2 (3.8%) | 3 (11.5%) | 1 (2.5%) | 0.120 | 6 (10.9%) | 0 | 0.009 |
Cough syrup | 4 (3.4%) | 0 | 4 (15.4%) | 0 | 0.001 | 4 (7.3%) | 0 | 0.034 |
Use of any medication^ | 110 (95%) | 46 (88%) | 25 (100%) | 39 (100%) | 0.020 | 49 (94%) | 61 (95%) | 0.794 |
Palivizumab n (%) | 0 (-) | 0 (-) | 0 (-) | 0 (-) | - | 0 (-) | 0 (-) | - |